Bionano Genomics director receives stock option grant
Bionano Genomics, Inc. director Yvonne Linney received a grant of stock options covering 9,149 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bionano Genomics, Inc. director Yvonne Linney received a grant of stock options covering 9,149 shares of common stock. The options have an exercise price of $1.19 per share and expire on May 13, 2036.
The award vests in equal monthly installments over 12 months, and will be fully vested by the company’s next annual stockholder meeting, subject to her continuous service. The options also vest in full upon a Change of Control as defined in the company’s 2018 equity incentive plan.
Insider Trade Summary
Grant/Award: 9,149 shares
Grant/Award
1 txn
Insider
Linney Yvonne
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 9,149 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,149 contracts (Direct)
Footnotes (1)
- F1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).
Key Figures
Option grant size: 9,149 options
Exercise price: $1.19 per share
Expiration date: May 13, 2036
+2 more
5 metrics
Option grant size
9,149 options
Stock Option (Right to Buy) awarded to director Yvonne Linney
Exercise price
$1.19 per share
Conversion or exercise price of granted stock options
Expiration date
May 13, 2036
Option term end date for Linney’s stock options
Shares underlying options
9,149 shares
Underlying common stock per Form 4
Vesting period
12 months
Equal monthly vesting following grant date
Key Terms
Stock Option (Right to Buy), Continuous Service, Change of Control, equity incentive plan
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Continuous Service financial
"subject to the option holder's Continuous Service through each such vesting date"
Change of Control financial
"will vest in full upon a Change of Control as defined in the Company's 2018 equity incentive plan"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
equity incentive plan financial
"as defined in the Company's 2018 equity incentive plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Bionano Genomics (BNGO) report for Yvonne Linney?
Bionano Genomics reported that director Yvonne Linney received a grant of 9,149 stock options. These options give her the right to buy common shares at $1.19 each, subject to vesting conditions over time and standard plan terms.
What is the size and strike price of the BNGO stock options granted to Yvonne Linney?
The grant to Yvonne Linney covers 9,149 stock options with an exercise price of $1.19 per share. This means she can later purchase up to 9,149 Bionano Genomics common shares at $1.19, once the options vest under the award’s schedule.
How do the Bionano Genomics (BNGO) options granted to Yvonne Linney vest?
The options vest in equal monthly installments over the 12 months following the grant date. They will in any case be fully vested by the company’s next annual stockholder meeting, provided she remains in continuous service through each vesting date.
When do Yvonne Linney’s BNGO stock options expire?
The stock options granted to Yvonne Linney expire on May 13, 2036. After that date, any unexercised options become worthless, so exercise is only possible from vesting dates through the stated expiration date, subject to the plan’s other conditions.
What happens to Yvonne Linney’s BNGO stock options if there is a Change of Control?
If a Change of Control occurs, the options vest in full immediately. The term “Change of Control” is defined in Bionano Genomics’ 2018 equity incentive plan and typically covers events like certain mergers or acquisitions affecting company ownership.
How many BNGO derivative securities does Yvonne Linney hold after this transaction?
Following this transaction, Yvonne Linney holds 9,149 derivative securities in the form of stock options. These options each relate to one share of Bionano Genomics common stock and are subject to the vesting and expiration terms disclosed in the award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates